To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

GSK’s chief commercial officer ... Zhifei also gets the right of first refusal to be the exclusive partner for Arexvy, which is not yet approved in China, but has been cleared in the US ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to ...

GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...

Commercial real estate brokers are required to have expertise in market data and financial analysis to best serve clients. They negotiate deals for various property types like office spaces ...

You will need commercial auto insurance if you're a business owner who drives a car, truck, van or other vehicle for business purposes. Commercial vehicle insurance provides similar coverages as ...

Shingrix sales reached 739 million pounds, down 7% at constant currency, with Arexvy sales of 188 million pounds, down 72%. Vaccine sales are expected to decrease at low-single-digit percent.

"We are pleased to announce positive head-to-head clinical data for our non-adjuvanted SCB-1019 RSV vaccine candidate compared to AS01E-adjuvanted AREXVY, indicating our potential best-in-class ...